Antisense & RNAi Therapeutics Global Market Report 2022 – By Technology (RNA Interference, Antisense RNA), By Route of Administration (Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery), By Indication (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 150 | Published : February 2022 | SKU CODE : 7709 | Delivery Time: 2-3 business days | Format :


The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition to this, antisense & RNAi therapeutics finds its application in curing cancer, infectious diseases, cardiovascular diseases, and genetic disorders.

The main technologies of antisense & RNAi therapeutics are RNA interference, antisense RNA. RNA interference is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids and regulates protein-coding gene expression. The various route of administration include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, other delivery methods that are used for the indication of oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, other.

The global antisense & RNAI therapeutics market size is expected to grow from $1.32 billion in 2021 to $1.42 billion in 2022 at a compound annual growth rate (CAGR) of 8%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The antisense and RNAi therapeutics market is expected to reach $2.14 billion in 2026 at a CAGR of 10.8%.

The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease is the most common neurodegenerative diseases affecting millions of people globally. In the USA, around 930,000 people had Parkinson’s disease by the end of 2020. Furthermore, according to the World Health Organization (WHO), infectious diseases are a major concern and dominated the WHO’s list of 2019 health threats ranging from various climate change issues to inadequate healthcare facilities. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market.

The high cost of RNA interference-based drugs is expected to act as a major restraint for the growth of the antisense & RNAi therapeutics market in the future. For instance, according to Future Medicine, the price of Onpattro is approximately $450,000 per year. Onpattro (patisaran) is the RNA interference-based drug used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Stringent regulations, long product approval process, high development cost, and a comparably small number of patients are few factors leading to the high cost of RNA interference drugs, which is expected to hinder the antisense & RNAi therapeutics’ market growth in upcoming years.

Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, and in or out-licensing deals. This trend has been increasing over recent years. For instance, in August 2020, Blackstone Life Sciences, a global investment company, and Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced the closing of a $2 billion strategic financing collaboration to accelerate the advancement and development of RNAi therapeutics. Under the agreement, Alnylam Pharmaceuticals, Inc. will receive $150 million from Blackstone Life Sciences for the development of vutrisiran and ALN-AGT, Alnylam’s cardiometabolic disease programs. In 2020, Aro Biotherapeutics Company has announced a licensing and collaboration agreement with Ionis Pharmaceuticals, Inc., the market leader in RNA-targeted therapeutics, under which Ionis will use Aro's CENTYRINTM technology to develop targeted cell- and tissue-specific delivery of antisense oligonucleotides (ASOs).

In November 2019, Novartis International AG, a Switzerland-based pharmaceutical company acquired The Medicines Company, a US-based biopharmaceutical company, for $9.7 million. With the acquisition of The Medicines Company, Novartis International AG plans to enter RNA therapeutics by acquiring its last stage RNA interference drug designed for protection against cardiovascular diseases in twice-yearly shorts. The drug has met the primary endpoint in the three phases of clinical trials and is approved for the treatment of cardiovascular diseases in the USA in 2019 and the EU in early 2020. The Medicines Company is a US-based company focused on the development of RNA drug inclisiran that is used in the treatment of renal impairment and cardiovascular diseases.

Major players in the antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics and Antisense Therapeutics Ltd.

The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the antisense & RNAi therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The global antisense & RNAi therapeutics market is segmented -

1) By Technology: RNA Interference, Antisense RNA

2) By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intra-Dermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods

3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Others

    Table Of Contents

    1. Executive Summary

    2. Antisense & RNAi Therapeutics Market Characteristics

    3. Antisense & RNAi Therapeutics Market Trends And Strategies

    4. Impact Of COVID-19 On Antisense & RNAi Therapeutics

    5. Antisense & RNAi Therapeutics Market Size And Growth

    5.1. Global Antisense & RNAi Therapeutics Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Antisense & RNAi Therapeutics Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Antisense & RNAi Therapeutics Market Segmentation

    6.1. Global Antisense & RNAi Therapeutics Market, Segmentation  By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    RNA Interference

    Antisense RNA

    6.2. Global Antisense & RNAi Therapeutics Market, Segmentation  By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Pulmonary Delivery

    Intravenous Injections

    Intra-dermal Injections

    Intraperitoneal Injections

    Topical Delivery

    Other Delivery Methods

    6.3. Global Antisense & RNAi Therapeutics Market, Segmentation  By Indication, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Oncology

    Cardiovascular Diseases (CVDs)

    Respiratory Disorders

    Neurological Disorders

    Infectious Diseases

    Other

    7. Antisense & RNAi Therapeutics Market Regional And Country Analysis

    7.1. Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Antisense & RNAi Therapeutics Market  

    8.1. Asia-Pacific Antisense & RNAi Therapeutics Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Antisense & RNAi Therapeutics Market  

    9.1. China Antisense & RNAi Therapeutics Market Overview  

    9.2. China Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Antisense & RNAi Therapeutics Market  

    10.1. India Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Antisense & RNAi Therapeutics Market  

    11.1. Japan Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Antisense & RNAi Therapeutics Market  

    12.1. Australia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Antisense & RNAi Therapeutics Market  

    13.1. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Antisense & RNAi Therapeutics Market  

    14.1. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Antisense & RNAi Therapeutics Market  

    15.1. Western Europe Antisense & RNAi Therapeutics Market Overview

    15.2. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Antisense & RNAi Therapeutics Market  

    16.1. UK Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Antisense & RNAi Therapeutics Market  

    17.1. Germany Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Antisense & RNAi Therapeutics Market  

    18.4. France Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.5. France Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Antisense & RNAi Therapeutics Market  

    19.1. Eastern Europe Antisense & RNAi Therapeutics Market Overview

    19.2. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Antisense & RNAi Therapeutics Market  

    20.1. Russia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Antisense & RNAi Therapeutics Market  

    21.1. North America Antisense & RNAi Therapeutics Market Overview

    21.2. North America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Antisense & RNAi Therapeutics Market  

    22.1. USA Antisense & RNAi Therapeutics Market Overview

    22.2. USA Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Antisense & RNAi Therapeutics Market  

    23.1. South America Antisense & RNAi Therapeutics Market Overview

    23.2. South America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Antisense & RNAi Therapeutics Market  

    24.1. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Antisense & RNAi Therapeutics Market  

    25.1. Middle East Antisense & RNAi Therapeutics Market Overview

    25.2. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Antisense & RNAi Therapeutics Market  

    26.1. Africa Antisense & RNAi Therapeutics Market Overview

    26.2. Africa Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Antisense & RNAi Therapeutics Market Competitive Landscape And Company Profiles

    27.1. Antisense & RNAi Therapeutics Market Competitive Landscape

    27.2. Antisense & RNAi Therapeutics Market Company Profiles

    27.2.1. Alnylam Pharmaceuticals

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Benitec Biopharma Ltd.

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Gene Signal

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. GlaxoSmithKline Plc

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Ionis Pharmaceuticals

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Antisense & RNAi Therapeutics Pipeline Analysis

    29. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market

    30. Antisense & RNAi Therapeutics Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Antisense & RNAi Therapeutics Market, Segmentation  By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Antisense & RNAi Therapeutics Market, Segmentation  By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Antisense & RNAi Therapeutics Market, Segmentation  By Indication, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Asia-Pacific, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: China, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: China, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: India, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: India, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: Japan, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: Japan, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: Australia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Australia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Indonesia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Indonesia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: South Korea, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: South Korea, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: Western Europe, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Western Europe, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: UK, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: UK, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Germany, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: Germany, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28: France, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29: France, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30: Eastern Europe, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31: Eastern Europe, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32: Russia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33: Russia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34: North America, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35: North America, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36: USA, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37: USA, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38: South America, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39: South America, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40: Brazil, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41: Brazil, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42: Middle East, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43: Middle East, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44: Africa, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45: Africa, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 46: Alnylam Pharmaceuticals Financial Performance
  • Table 47: Benitec Biopharma Ltd. Financial Performance
  • Table 48: Gene Signal Financial Performance
  • Table 49: GlaxoSmithKline Plc Financial Performance
  • Table 50: Ionis Pharmaceuticals Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global Antisense & RNAi Therapeutics Market, Segmentation  By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global Antisense & RNAi Therapeutics Market, Segmentation  By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global Antisense & RNAi Therapeutics Market, Segmentation  By Indication, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Asia-Pacific, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Asia-Pacific, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: China, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: China, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: India, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: India, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: Japan, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: Japan, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: Australia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: Australia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: Indonesia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Indonesia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: South Korea, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: South Korea, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: Western Europe, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: Western Europe, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: UK, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: UK, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: Germany, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27: Germany, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 28: France, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 29: France, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 30: Eastern Europe, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 31: Eastern Europe, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 32: Russia, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 33: Russia, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 34: North America, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 35: North America, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 36: USA, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 37: USA, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 38: South America, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 39: South America, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 40: Brazil, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 41: Brazil, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 42: Middle East, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 43: Middle East, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 44: Africa, Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 45: Africa, Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 46: Alnylam Pharmaceuticals Financial Performance
  • Figure 47: Benitec Biopharma Ltd. Financial Performance
  • Figure 48: Gene Signal Financial Performance
  • Figure 49: GlaxoSmithKline Plc Financial Performance
  • Figure 50: Ionis Pharmaceuticals Financial Performance
Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Therapeutic Proteins Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Nucleic Acid Based Gene Therapy Global Market Report 2022 – By Technology (Anti-Sence And Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers), By Application (Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases), By End User (Hospitals And Clinics, Academic And Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Respiratory Devices And Equipment (Diagnostic) Global Market Report 2022 – By Product (Instruments And Devices, Assays And Reagents), By Test Type (Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular Diagnostic Tests), By Disease Type (Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis), By End-User (Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Respiratory Devices And Equipment (Therapeutic And Diagnostic) Global Market Report 2022 – By Type (Diagnostic devices, Therapeutic devices, Monitoring devices), By End User (Hospitals, Clinics, Homecare settings, Ambulatory service centers), By Therapeutic Devices (Humidifiers, Nebulizers, Oxygen concentrators, Positive Airway Pressure (PAP) Devices, Ventilators), By Diagnostic Devices (Spirometer, Polysomnographs, Peak Flow Meters), By Monitoring Devices (Pulse oximeters, Capnographs, Gas analyzers), By Application (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Obstructive Sleep Apnea (OSA), Respiratory Distress Syndrome (RDS), Cystic Fibrosis, Pneumonia) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Respiratory Monitoring Devices Global Market Report 2022 – By Type (Capnographs, Gas Analyzers, Pulse Oximeters, Peak Flow Meters, Spirometers, Polysomnographs), By End-User (Laboratories, Hospitals, Home Use), By Application (Chronic Obstructive Pulmonary Disease (COPD), Infectious Diseases, Asthma) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Oligonucleotide Therapy Global Market Report 2022 – By Type (Antisense Oligonucleotide, Aptamer), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases), By End User (Hospitals, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Pulmonologists Global Market Report 2020 - By Practice (Owner-Solo Practice, Owner - Group Practice, Partner), By Disease (Chronic Obstructive Pulmonary Disease , Obstructive Sleep Apnea, Pulmonary Hypertension, Tuberculosis, Asthma And Allergy, Interstitial Lung Disease, Pneumonia, Lung Cancer, Cardio Pulmonary Disorders), COVID-19 Implications And Growth
View Report
Respiratory Disposables Global Market Report 2022 – By Type (Masks, Tubes, Inhalers, Other Types), By End User (Hospitals, Clinics, Ambulatory Care Centers, Other End Users), By Disease Indications (Asthma, Chronic Obstructive Pulmonary Disorder, Tuberculosis, Lung Cancer, Other Chronic Respiratory Diseases), By Application (Adult, Pediatric & Neonatal) – Market Size, Trends, And Global Forecast 2022-2026
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)